Physician profile
Christopher H Chu
NPI 1699271551
$26,237.52
in general payments reported to CMS, 2019-2025
19 companies · $14K in 2025
The $14K reported for 2025 was more than what 92% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.91 · 2022: $889 · 2023: $1,586 · 2024: $9,260 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $8,759 · Travel and Lodging: $2,167 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,165.34 |
| Food and Beverage | $8,759.29 |
| Travel and Lodging | $2,167.07 |
| Education | $188.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $9,929.15 | 2023-2025 | Andembry, Haegarda |
| Regeneron Healthcare Solutions, INC. | $5,228.53 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $4,584.33 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Abbvie INC. | $1,391.39 | 2022-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $989.64 | 2023-2025 | Takhzyro, Cuvitru |
| Glaxosmithkline, LLC. | $669.46 | 2022-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Amgen INC. | $666.70 | 2023-2025 | Tezspire |
| Genzyme Corporation | $664.69 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $541.74 | 2024-2025 | Orladeyo |
| Blueprint Medicines Corporation | $403.24 | 2024-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $361.24 | 2024-2025 | |
| Pharming Healthcare, INC. | $260.12 | 2024-2025 | Ruconest |
| Grifols USA, LLC | $156.98 | 2023-2024 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $146.40 | 2025 | Neffy |
| Incyte Corporation | $106.54 | 2024-2025 | Opzelura |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $62.69 | 2025 | Dawnzera |
| Kaleo, INC. | $38.94 | 2023-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $19.51 | 2023 | |
| Optinose US, INC. | $16.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.